TISOTUMAB VEDOTIN-TFTV: 560 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

560

Total FAERS Reports

39 (7.0%)

Deaths Reported

Hospitalizations

560

As Primary/Secondary Suspect

Life-Threatening

Disabilities

Prescription

Status

FDA Application: 761208 ·

First Report: 20211122 · Latest Report: 20250825

What Are the Most Common TISOTUMAB VEDOTIN-TFTV Side Effects?

#1 Most Reported

Neuropathy peripheral

44 reports (7.9%)

#2 Most Reported

Nausea

36 reports (6.4%)

#3 Most Reported

Rash

31 reports (5.5%)

Side Effect	Reports	% of Total	Deaths	Hosp.
Neuropathy peripheral	44	7.9%	0	8
Nausea	36	6.4%	2	7
Dry eye	31	5.5%	1	2
Rash	31	5.5%	0	6
Malignant neoplasm progression	28	5.0%	3	3
Off label use	28	5.0%	0	1
Death	27	4.8%	26	2
Weight decreased	23	4.1%	0	1
Eye disorder	22	3.9%	1	2
Fatigue	22	3.9%	0	1
Product temperature excursion issue	22	3.9%	0	0
Alopecia	18	3.2%	0	4
Conjunctivitis	18	3.2%	0	1
Diarrhoea	14	2.5%	0	6
Epistaxis	14	2.5%	0	0
Ocular toxicity	14	2.5%	0	1
Vomiting	14	2.5%	2	3
Abdominal pain	12	2.1%	1	4
Constipation	12	2.1%	0	3
Pyrexia	12	2.1%	0	6

Gender: 99.6% female, 0.4% male. Average age: 53.3 years. Most reports from: US. View detailed demographics →

Year	Reports	Deaths	Hosp.
2021	5	0	0
2022	45	5	9
2023	42	6	5
2024	49	6	12
2025	48	1	16

Indication	Reports
Product used for unknown indication	199
Cervix carcinoma	163
Cervix carcinoma recurrent	47
Cervix cancer metastatic	10
Squamous cell carcinoma of the cervix	10

Official prescribing information from the FDA-approved drug label.